OBJECTIVE: Drug induced dyskinesias remain a challenging problem in the long term management of Parkinson's disease (PD). We have assessed the effect of quetiapine on dyskinesias in a double blind placebo controlled cross over study. METHODS: Nine patients with PD were enrolled and received 25 mg of quetiapine or placebo at night for two weeks in prerandomised order, with one week of wash out between treatment periods. Assessments were made using on-off diaries, self assessment of dyskinesias, and L-dopa challenges at baseline and after each treatment period. Videotapes were rated blindly by two raters using modified Abnormal Involuntary Movement Scale and Goetz scores. Patients subsequently went on open label quetiapine at 50 mg/day, for a...
INTRODUCTION: Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing movement ...
BACKGROUND: Orthostatic hypotension (OH) is multifactorial in Parkinson's disease (PD). Antiparkinso...
Objectives - The aim of this study was to investigate the clinical efficacy of clozapine, an atypica...
OBJECTIVES: Mental disorders (MDs) are disabling complications of Parkinson disease (PD). We set out...
Objective: The purpose of this article was to determine the efficacy and tolerability of quetiapine ...
BACKGROUND: Despite optimum medical management, many patients with Parkinson's disease are incapacit...
Although quetiapine is the antipsychotic of choice for the psychosis associated with Parkinson’s dis...
Drug-induced parkinsonism (DIP) has been known for >60 years. It is the second leading cause of park...
Background: Antipsychotic medication can cause tardive dyskinesia (TD) – late-onset, involuntary, re...
The atypical antipsychotics were believed to induce less extrapyramidal syndrome, including tardive ...
Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's dise...
INTRODUCTION: Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing movement ...
BACKGROUND: Orthostatic hypotension (OH) is multifactorial in Parkinson's disease (PD). Antiparkinso...
Objectives - The aim of this study was to investigate the clinical efficacy of clozapine, an atypica...
OBJECTIVES: Mental disorders (MDs) are disabling complications of Parkinson disease (PD). We set out...
Objective: The purpose of this article was to determine the efficacy and tolerability of quetiapine ...
BACKGROUND: Despite optimum medical management, many patients with Parkinson's disease are incapacit...
Although quetiapine is the antipsychotic of choice for the psychosis associated with Parkinson’s dis...
Drug-induced parkinsonism (DIP) has been known for >60 years. It is the second leading cause of park...
Background: Antipsychotic medication can cause tardive dyskinesia (TD) – late-onset, involuntary, re...
The atypical antipsychotics were believed to induce less extrapyramidal syndrome, including tardive ...
Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's dise...
INTRODUCTION: Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing movement ...
BACKGROUND: Orthostatic hypotension (OH) is multifactorial in Parkinson's disease (PD). Antiparkinso...
Objectives - The aim of this study was to investigate the clinical efficacy of clozapine, an atypica...